Search research articles
Contact Us
Filters
Showing results (71-80 of 136) with videos related to
Page
of 14
Sort By:
JCO Precision Oncology
|
September 11, 2020
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With <i>BRAF</i>-Mutated Malignancies
Vivek Subbiah, Shiraj Sen, Kenneth R Hess, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
August 22, 2025
A phase 1B trial of vocimagene amiretrorepvec in patients with advanced solid tumors: Safety, tumor homing, and immune modulatory effects
Jaime R Merchan, Jordi Rodon, Shree Venkat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2012
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
Filip Janku, Jennifer J Wheler, Shannon N Westin, et al.
Oncotarget
|
June 11, 2014
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
Jennifer J Wheler, Stacy L Moulder, Aung Naing, et al.
Molecular Cancer Therapeutics
|
January 11, 2011
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
Filip Janku, Apostolia M Tsimberidou, Ignacio Garrido-Laguna, et al.
Oncotarget
|
December 19, 2012
PIK3CA mutations in advanced cancers: characteristics and outcomes
Filip Janku, Jennifer J Wheler, Aung Naing, et al.
Cancer Chemotherapy and Pharmacology
|
January 18, 2014
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers
Jennifer J Wheler, Filip Janku, Gerald S Falchook, et al.
Oncoscience
|
January 17, 2015
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors
Chad Tang, Denis L Fontes Jardim, Gerald S Falchook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2012
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors
David S Hong, Daniel W Bowles, Gerald S Falchook, et al.
Oncotarget
|
February 9, 2013
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials
Ishwaria M Subbiah, Vivek Subbiah, Apostolia M Tsimberidou, et al.
Page
of 14
Search research articles
Search
Showing results (71-80 of 136) with videos related to
Sort By:
Page
of 14
JCO Precision Oncology
|
September 11, 2020
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With <i>BRAF</i>-Mutated Malignancies
Vivek Subbiah, Shiraj Sen, Kenneth R Hess, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
August 22, 2025
A phase 1B trial of vocimagene amiretrorepvec in patients with advanced solid tumors: Safety, tumor homing, and immune modulatory effects
Jaime R Merchan, Jordi Rodon, Shree Venkat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2012
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
Filip Janku, Jennifer J Wheler, Shannon N Westin, et al.
Oncotarget
|
June 11, 2014
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
Jennifer J Wheler, Stacy L Moulder, Aung Naing, et al.
Molecular Cancer Therapeutics
|
January 11, 2011
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
Filip Janku, Apostolia M Tsimberidou, Ignacio Garrido-Laguna, et al.
Oncotarget
|
December 19, 2012
PIK3CA mutations in advanced cancers: characteristics and outcomes
Filip Janku, Jennifer J Wheler, Aung Naing, et al.
Cancer Chemotherapy and Pharmacology
|
January 18, 2014
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers
Jennifer J Wheler, Filip Janku, Gerald S Falchook, et al.
Oncoscience
|
January 17, 2015
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors
Chad Tang, Denis L Fontes Jardim, Gerald S Falchook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 14, 2012
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors
David S Hong, Daniel W Bowles, Gerald S Falchook, et al.
Oncotarget
|
February 9, 2013
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials
Ishwaria M Subbiah, Vivek Subbiah, Apostolia M Tsimberidou, et al.
Page
of 14